Quoin Pharmaceuticals Ltd ADR (NASDAQ:QNRX)’s traded shares stood at 0.86 million during the last session, with the company’s beta value hitting 1.79. At the close of trading, the stock’s price was $0.80, to imply an increase of 6.68% or $0.05 in intraday trading. The QNRX share’s 52-week high remains $6.18, putting it -672.5% down since that peak but still an impressive 40.0% since price per share fell to its 52-week low of $0.48. The company has a valuation of $4.04M, with an average of 4.51 million shares in intraday trading volume over the past 10 days and average of 3.31 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Quoin Pharmaceuticals Ltd ADR (QNRX), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give QNRX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.43.
Quoin Pharmaceuticals Ltd ADR (NASDAQ:QNRX) trade information
After registering a 6.68% upside in the last session, Quoin Pharmaceuticals Ltd ADR (QNRX) has traded red over the past five days. The 5-day price performance for the stock is 33.35%, and 10.13% over 30 days. With these gigs, the year-to-date price performance is -83.69%. Short interest in Quoin Pharmaceuticals Ltd ADR (NASDAQ:QNRX) saw shorts transact 19172.0 shares and set a 0.2 days time to cover.
Quoin Pharmaceuticals Ltd ADR (QNRX) estimates and forecasts
Looking at statistics comparing Quoin Pharmaceuticals Ltd ADR share performance against respective industry, we note that the company has outperformed competitors. Quoin Pharmaceuticals Ltd ADR (QNRX) shares are 11.13% up over the last 6 months, with its year-to-date growth rate higher than industry average at 78.73% against 16.60%.
QNRX Dividends
Quoin Pharmaceuticals Ltd ADR has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Quoin Pharmaceuticals Ltd ADR (NASDAQ:QNRX)’s Major holders
Quoin Pharmaceuticals Ltd ADR insiders hold 2.45% of total outstanding shares, with institutional holders owning 5.89% of the shares at 6.03% float percentage. In total, 5.89% institutions holds shares in the company.
